Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant (NCT05424003)
A Randomized Double Blinded Placebo-Controlled Trial of Semaglutide to Prevent Weight Gain Following Liver Transplantation
🩺 Plain-English Summary (8th-Grade Level)
In this study, semaglutide will be compared to placebo (a look-alike inactive substance, a "sugar pill") to determine if its use will prevent weight gain after liver transplantation (LT). In addition, researchers will be testing to determine if semaglutide prevents the development of Non-Alcoholic Fatty Liver Disease (NAFLD) after transplant through Magnetic Resonance Imaging (MRI) and laboratory results.
Who can join: Review the eligibility criteria below.
Location: Virginia Commonwealth University — Richmond, Virginia
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Virginia Commonwealth University — Richmond, Virginia
📞 Contact the Study Coordinator
Phone: (804) 828-5434
Email: sherry.boyett@vcuhealth.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in NAFLD
- Accurate Point of Care Liver Disease Diagnostics — La Jolla, California
- Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD — Iowa City, Iowa
- Nonalcoholic Fatty Liver Disease in HIV Database — Birmingham, Alabama
- LITMUS Imaging Study — San Antonio, Texas
- An Imaging-based Quantitative Biomarker Assay for NAFLD in Children — Madison, Wisconsin
- Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV — Tuscaloosa, Alabama
Explore by condition: All NAFLD clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.